Rubicon Research liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
17.48×—
2.01×2.01×
1.14×1.14×
186186
846846
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RUBICON₹1,559.30

Rubicon Research Ltd.

· Pharma & Health
₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹25,742 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)—17.48
Current Ratio2.012.01
Quick Ratio1.141.14
Cash, Equiv & ST Investments185.7185.7
Working Capital845.9845.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.